J&J Unit Slams Diabetes Drug Blood Disorder Claims

Law360, Philadelphia (March 8, 2016, 5:07 PM EST) -- A Johnson & Johnson unit has hit back at allegations that its Type 2 diabetes drug Invokana caused a man to contract the potentially life-threatening condition diabetic ketoacidosis, telling a Pennsylvania court that his drug design defect claims were federally preempted.

In Feb. 29 preliminary objections to the complaint, Janssen Pharmaceuticals Inc. pointed to a trio of U.S. Supreme Court rulings that purportedly clarified the test for preemption issues, saying that the principles expressed applied to both branded and generic drugs.

“First, courts should identify what action the plaintiff’s state-law claim would require the defendant to take,” the drugmaker said. “Second,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related

Sections

Law Firms

Companies

Government Agencies